Evidence map›Paper›PMID 37655686›Full record

ArticleJournal of comparative effectiveness research2023

Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.

Jon Apple, Maral DerSarkissian, Anne Shah, Rose Chang, Yan Chen, Xuanhao He, Justin Chun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Budget impact analysis of neoadjuvant nivolumab for non-small cell lung cancer in the Chilean public healthcare system: An exploratory economic assessment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jon AppleAstraZeneca Pharmaceuticals, One MedImmune Way, Gaithersburg, MD 20878, USA.
Maral DerSarkissianAnalysis Group, 333 South Hope Street, 27th Floor, Los Angeles, CA 90071, USA.
Anne ShahAstraZeneca Pharmaceuticals, One MedImmune Way, Gaithersburg, MD 20878, USA.
Rose ChangAnalysis Group, 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA.
Yan ChenAnalysis Group, 333 South Hope Street, 27th Floor, Los Angeles, CA 90071, USA.
Xuanhao HeAnalysis Group, 333 South Hope Street, 27th Floor, Los Angeles, CA 90071, USA.
Justin ChunAnalysis Group, 333 South Hope Street, 27th Floor, Los Angeles, CA 90071, USA.

Funding

NCI NIH HHS HHSN261201800009CNCI NIH HHS HHSN261201800009INCI NIH HHS HHSN261201800015CNCI NIH HHS HHSN261201800015INCI NIH HHS HHSN261201800032CNCI NIH HHS HHSN261201800032I
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSmall Cell Lung CarcinomaAgedChemotherapy, AdjuvantFinancial StressHumansMedicareNeoplasm StagingPatient Acceptance of Health CareUnited Statesadjuvant therapyearly-stageeconomic burdenhealthcare resource utilizationmedical costsnon-small-cell lung cancer

Identifiers

PMID37655686
PMCPMC10690396

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.